Overview

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Status:
Not yet recruiting

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Collaborator:

AbbVie

Treatments:

Venetoclax